July 2022 Br J Cardiol 2022;29:89–94 doi:10.5837/bjc.2022.023
John P Sheppard, Suvasini Lakshmanan, Seth J Lichtenstein, Matthew J Budoff, Sion K Roy
Introduction Since its inception by Agatston and Janowitz in 1990, coronary artery calcium (CAC) scoring has blossomed from a novel imaging tool to an internationally accepted biomarker of cardiovascular risk included in current preventive atherosclerotic cardiovascular disease (ASCVD) guidelines.1-7 With its growing adoption, debate has emerged over the proper use of CAC scores in risk stratification, with controversy surrounding its role in excluding obstructive disease in symptomatic patients. Presently, we focus on the role of CAC in risk stratification for coronary heart disease (CHD). We review the overwhelming evidence validating CAC
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits